Literature DB >> 27207483

Stenotrophomonas maltophilia ventilator-associated pneumonia. A retrospective matched case-control study.

Johannes B J Scholte1,2, Tan Lai Zhou2, Dennis C J J Bergmans2, Gernot G U Rohde3, Bjorn Winkens4, Helke A Van Dessel5, Tom P J Dormans6, Catharina F M Linssen7, Paul M H J Roekaerts2, Paul H M Savelkoul5,8, Walther N K A van Mook2.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia is increasingly identified in critically ill patients, but it is considered a pathogen with limited pathogenicity and it is therefore infrequently targeted. This study explores whether S. maltophilia may cause ventilator-associated pneumonia (VAP) and whether it affects intensive care unit (ICU) mortality and 28-day mortality when compared to VAP caused by other Gram-negative bacilli.
METHODS: Retrospective analysis of a 19-year prospectively collected database. Stenotrophomonas maltophilia as a cause was considered in VAP-suspected cases when S. maltophilia growth of ≥10(4) cfu/ml was detected in bronchoalveolar lavage fluid analysis. Cases were matched on hospital, gender, age and acute physiology and chronic health evaluation II score in a 1:3 ratio with controls from the same database suffering from VAP caused by other Gram-negative bacilli.
RESULTS: Eight cases met the inclusion criteria, of which three were labelled as 'probable' SM-VAP and three as 'possible' SM-VAP. These six patients constitute 1.8% of all VAPs in the studied period. No significant differences in baseline characteristics and duration of mechanical ventilation (p = 0.68), length of stay in the ICU (p = 0.55) and hospital (p = 0.84) between cases and controls were identified between cases and controls. Intensive care unit mortality odds ratio was 1.7 (p = 0.55; 95% CI 0.3-10.5) and 28-day mortality odds ratio was 1.4 (p = 0.70; 95% CI 0.2-9.1).
CONCLUSIONS: Stenotrophomonas maltophilia is a possible, yet infrequent cause of VAP. No outcome differences were found when compared to matched VAP caused by other Gram-negative bacilli.

Entities:  

Keywords:  Intensive care unit; Stenotrophomonas maltophilia; mechanical ventilation; mortality; multidrug-resistant; ventilator-associated pneumonia

Mesh:

Year:  2016        PMID: 27207483     DOI: 10.1080/23744235.2016.1185534

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  6 in total

1.  Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Authors:  Iris H Chen; James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

2.  An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious Diseases Society of America/American Thoracic Society guidelines.

Authors:  Lyn S Awad; Dania I Abdallah; Anas M Mugharbil; Tamima H Jisr; Nabila S Droubi; Nabila A El-Rajab; Rima A Moghnieh
Journal:  Infect Drug Resist       Date:  2017-12-22       Impact factor: 4.003

3.  Risk Factors for Acquired Stenotrophomonas maltophilia Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis.

Authors:  Neng Wang; Congchen Tang; Lichun Wang
Journal:  Front Med (Lausanne)       Date:  2022-01-12

4.  Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature.

Authors:  Giulia Jole Burastero; Gabriella Orlando; Antonella Santoro; Marianna Menozzi; Erica Franceschini; Andrea Bedini; Adriana Cervo; Matteo Faltoni; Erica Bacca; Emanuela Biagioni; Irene Coloretti; Gabriele Melegari; Jessica Maccieri; Stefano Busani; Elisabetta Bertellini; Massimo Girardis; Giulia Ferrarini; Laura Rofrano; Mario Sarti; Cristina Mussini; Marianna Meschiari
Journal:  Antibiotics (Basel)       Date:  2022-07-26

5.  Serial platelet level index improves prediction of pulmonary hemorrhage in patients with Stenotrophomonas maltophilia respiratory infections and thrombocytopenia.

Authors:  Huai-Chueh Gem Wu; Huai-Shing Wu; Chao-Neng Cheng; Jiann-Shiuh Chen; Tsai-Yun Chen; Chung-I Li; Ching-Fen Shen
Journal:  Front Med (Lausanne)       Date:  2022-09-02

6.  Prognosis of hospital-acquired pneumonia/ventilator-associated pneumonia with Stenotrophomonas maltophilia versus Klebsiella pneumoniae in intensive care unit: A retrospective cohort study.

Authors:  Shuping Chen; Dongdong Zou
Journal:  Clin Respir J       Date:  2022-08-31       Impact factor: 1.761

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.